IVERIC bio, Inc.: management transactions · United States · SEC (Form 4)

About IVERIC bio, Inc.

IVERIC bio, Inc. is a United States-based ophthalmology-focused biopharmaceutical company historically listed on the NASDAQ under the ticker ISEE. The company was originally incorporated in 2007 as Ophthotech Corporation and later rebranded as IVERIC bio to reflect its strategic pivot toward retinal biology and novel eye-disease therapeutics. Its corporate footprint has been associated with Parsippany, New Jersey, and its business model has been that of a highly specialized, research-driven biotech rather than a broad diversified pharmaceutical group. The company’s core story has centered on avacincaptad pegol, also known as ACP and branded Zimura, a complement C5 inhibitor developed for geographic atrophy secondary to age-related macular degeneration (AMD). This asset became the company’s lead program and the main driver of both investor attention and strategic value. In practice, IVERIC bio built its reputation around a narrow but deep clinical pipeline aimed at severe retinal disorders with significant unmet medical need. It also pursued additional early-stage programs, including IC-500, but the investment case was overwhelmingly defined by the progress of its lead ophthalmic candidate. From a competitive standpoint, IVERIC bio operated in a market characterized by high scientific barriers, limited direct competition in geographic atrophy at the time, and significant commercial opportunity if a disease-modifying therapy could reach patients. The company’s strategy reflected the economics of specialty biotech: focus capital and scientific resources on one high-potential asset, build manufacturing and supply capabilities, and seek regulatory and commercial inflection points that could materially change valuation. Its positioning was therefore more concentrated than that of larger ophthalmology franchises at multinational drugmakers, but potentially more leveraged to clinical success. Key business lines included clinical development, regulatory preparation, and commercialization readiness around its lead retinal therapy. The company also entered into manufacturing and supply agreements to support large-scale production of the active pharmaceutical ingredient, underscoring its transition from pure development toward a potential commercial-stage profile. These operational steps were important because they signaled preparedness for launch execution, not just clinical readouts. Recent developments in the public record show that IVERIC bio’s path became closely tied to the fate of avacincaptad pegol and to major corporate actions disclosed in SEC filings. In 2023, the company entered into a merger agreement that ultimately changed its independent trajectory, making the stock a classic example of a biotech story shaped by one lead asset, regulatory milestones, and transaction-driven outcomes. For investors in France, Belgium, and Switzerland, IVERIC bio is best understood as a US NASDAQ-listed ophthalmic biotech whose history, pipeline, and market value were driven primarily by a single late-stage retinal program and the strategic optionality around it.